secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-061401
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte enters into Master Services Agreement with Lonza for manufacturing of VAX-24 and VAX-31 components
--------------------------------------------------------------------------------

- Agreement effective March 1, 2023, for manufacturing process development and production of polysaccharide antigens, eCRM carrier, and conjugated drug substances.
- Vaxcyte owns IP directly derived from its materials or improvements to its background IP; Lonza owns generally applicable IP and improvements to its background IP.
- Lonza grants Vaxcyte a non-exclusive, worldwide, fully paid-up, transferable license under new general application IP for products manufactured under the agreement.
- Initial term of five years with automatic renewal for two years unless either party gives two years' non-renewal notice before the fifth anniversary.
- Either party may terminate for material breach, insolvency, extended force majeure, or scientific/technical impossibility; Vaxcyte may also terminate on a project-by-project basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523061401/0001193125-23-061401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312523061401/d476717d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-061401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer